Clinician

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

Retrieved on: 
월요일, 5월 6, 2024
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Other Technology, Software, Artificial Intelligence, Clinical Trials, Enzyme, Cancer, Prostate, IP, D.C, PDI, Proteinopathy, PMID, Drug resistance, Machine learning, The Journal of Pathology, Breast, MD, Cell, Artificial intelligence, Leukemia, ISSN, Cancer Medicine, Molecular biology, CNS, Giaquinto, Algorithm, Patient, Neoplasm, Lung, Death, Head, Biomarker, Drug development, Therapy, Clinician, Journal, Ovarian cancer, Brain, Oncology Reports, Pharmaceutical industry

(NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.

Key Points: 
  • (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.
  • Oregon Therapeutics is developing XCE853 in various cancer indications, including drug-resistant ovarian and pancreatic cancer, certain hematological cancers and several pediatric cancers including CNS cancers.
  • Oregon Therapeutic’s lead drug-candidate XCE853 is known to target PDIs of specific interest for cancer.
  • Oregon Therapeutics is entitled to financial benefits resulting from the out licensing of the background IP to Lantern Pharma.

Encore Clinical Holdings Corp Acquires Primus Wound Care, Becoming the Largest Wound Care Provider in Ohio

Retrieved on: 
수요일, 3월 13, 2024
Patient, Documentation, Clinician, Acquisition, Nursing

CLEVELAND, March 13, 2024 /PRNewswire/ -- Encore Clinical Holdings Corp is thrilled to announce the acquisition of Primus Wound Care, marking a significant expansion in its services, and establishing itself as the largest provider of wound care in Ohio.

Key Points: 
  • CLEVELAND, March 13, 2024 /PRNewswire/ -- Encore Clinical Holdings Corp is thrilled to announce the acquisition of Primus Wound Care, marking a significant expansion in its services, and establishing itself as the largest provider of wound care in Ohio.
  • Primus Wound Care, founded by Dan Borison, has been recognized for its outstanding team of clinicians and management, who are committed to delivering exceptional care and results.
  • This acquisition aligns with Encore Clinical Holdings' mission to provide superior outcomes for patients and enhance the services offered to facility partners.
  • This acquisition represents a landmark moment for Encore Clinical Holdings Corp, reinforcing its commitment and mission to delivering high-quality wound care and expanding its services to meet the growing needs of patients across Ohio and Pennsylvania and beyond.

10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring

Retrieved on: 
월요일, 3월 11, 2024
CSFS, PSFS, Biotechnology, Elective surgery, Bruise, Patient, SAN, Abdomen, American Academy, MD, Clinician, Clinical trial, American Academy of Dermatology, Erythema, ITT, FAAD, Pain, AAD, FDA, Organic acid, Edema, Annual general meeting, Pharmaceutical industry

SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101. An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.

Key Points: 
  • SAN DIEGO, March 11, 2024 /PRNewswire/ -- 10xBio , LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today promising initial clinical trial results on its novel injectable drug for submental body contouring, 10XB101.
  • An innovative alternative to other fat removal options, 10XB101 provides superior efficacy, fewer side effects, enhanced patient tolerability and shorter treatment intervals.
  • "10XB101 has the appropriate product-market fit to capture the tremendous opportunity for submental contouring.
  • In addition, its attributes hold promise for potential expansion to other body contouring applications, such as treatment of the abdomen and flanks."

National Study Finds AI Use in Healthcare Delivery Hampered by Trust, Training and Liability Fears

Retrieved on: 
월요일, 2월 26, 2024
Algorithm, Internal medicine, Digital, AI, Gen, Physician, Health, Generative, Public health, Cardiology, Providers, ChatGPT, Risk, Oncology, Synthetic media, LLM, Patient, Optimism, Policy, Primary care, Clinician, Trust, Medical device

More than half believe AI can save them time (57%) and that it will transform healthcare delivery (56%), while exactly half (50%) believe AI use can help them deliver better patient care.

Key Points: 
  • More than half believe AI can save them time (57%) and that it will transform healthcare delivery (56%), while exactly half (50%) believe AI use can help them deliver better patient care.
  • Yet despite high levels of personal use and optimism for its future impact in healthcare, clinicians remain wary of using AI for healthcare in the near term.
  • And they don’t trust that AI will reduce liability: 4 in 10 believe that AI use will put them at greater risk of liability.
  • Training: Nearly half (42%) of clinicians are unprepared for implementation of Gen AI into their practice but 50% agree that implementation will require new training.

Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)

Retrieved on: 
월요일, 11월 27, 2023
Storm, Clinician, Earthquake, Anglo-French Wars, Behavior, Safety, Wildfire, Therapy, DSM-IV codes, Post-traumatic stress disorder, Incidence, Flood, Toxicology, Operation Iraqi Freedom documents, Freedom, Veterans' affairs, Male, Trauma, Veteran, Suicide, Vietnam War, Accident, Biomarker, Low-threshold treatment programs, Female, DOD, World War II, Pharmaceutical industry, Defense, Korean War, PTSD

NEW YORK, Nov. 27, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that SLS-002 (intranasal racemic ketamine) has been selected for inclusion in an adaptive platform trial to evaluate treatments for post-traumatic stress disorder (PTSD) in active-duty service members and veterans. The trial is funded by the U.S. Department of Defense's (DOD) Defense Health Agency and led by the Warfighter Readiness, Performance, and Brain Health Project Management Office, part of the U.S. Army Medical Materiel Development Activity.

Key Points: 
  • "We would like to thank the project managers and subcontractors to this study for their tireless effort in moving this program forward.
  • In addition, the trial will evaluate several biomarkers associated with PTSD and assessments of treatment safety and tolerability.
  • "This study provides an ideal opportunity to study SLS-002 for PTSD," said Tim Whitaker, M.D., Chief Medical Officer of Seelos.
  • "The current approved pharmacologic treatments for PTSD have a number of limitations, and there remains a high unmet medical need.

Daytryp Health Announces Partnership with Enthea for Groundbreaking Nationwide Availability of Ketamine-Assisted Therapy as an Employee Benefit

Retrieved on: 
수요일, 11월 8, 2023
Ketamine, DSM-5, MD, News, Health, Dr. Bronner's Magic Soaps, KAT, Doctor, Clinician, PTSD, Partnership, Brain, Depression, Patient, Mental health, Pharmaceutical industry

PHOENIX, Nov. 8, 2023 /PRNewswire-PRWeb/ -- Daytryp Health, Arizona's premier Ketamine Assisted Treatment (KAT) organization, which focuses on using Ketamine Therapy for a variety of mental health ailments, has entered into a partnership with Enthea.

Key Points: 
  • Chris Cohn, CEO of Daytryp Health
    Enthea is the first and only licensed provider of health benefit plans that cover psychedelic-assisted therapies.
  • Enthea is delighted to announce that it now has national network capabilities and is able to serve not only Arizona employers, but U.S. employers nationwide.
  • Daytryp is proud to partner with Enthea to help future-thinking employers offer Ketamine Therapy which have long lasting, transformative outcomes," said Chris Cohn, CEO of Daytryp Health.
  • This can result in long-term relief – and not merely symptom suppression, as is too often the case with today's conventional therapy."

Majority of Medical and Nursing Students Planning Careers Outside Patient Care, as Fears of Burnout and Clinician Shortages Leave Them Worried About the Future

Retrieved on: 
월요일, 10월 30, 2023
Faculty, APRN, Education, RNS, Life, Access, Bureau of Labor Statistics, ChatGPT, Workforce, Health, Bureau, Learning, Health education, Curriculum, Washington University School of Medicine, Pulse, CNE, Medicine, American Hospital Association, Student, Hospital, CHSE, DNP, Retirement, George Washington University School of Nursing, Depression, Future, Nursing, Patient, Pharmaceutical industry, Elsevier, Osmosis, Clinician

Elsevier Health's first global "Clinician of the Future 2023: Education Edition" highlights students' deep concerns about balancing their commitment to patient care with their own well-being. The report also identifies key insights into students' excitement and fears toward technology and AI in healthcare education.

Key Points: 
  • Now, in my fourth year and preparing for the next step of residency training, I am reflecting on the reality of entering the workforce.
  • My peers and I have discussed what our soon-to-be realities might look like between exhausting residency expectations, staff shortages, patient backlogs and the potential toll on our overall well-being.
  • Additionally, the Bureau of Labor Statistics projects there will be 203,200 openings for RNs each year through 2031.
  • Hosting webinars on resilience and depression in healthcare, as well as developing podcast episodes relevant to healthcare challenges

IKS Health Purchases AQuity Solutions to Create the Most Comprehensive Provider of Administrative, Clinical and Financial Services for Healthcare Organizations in the U.S.

Retrieved on: 
화요일, 10월 31, 2023
Digital, Health status of Asian Americans, Health care, HIPAA, Black Book, Synthetic media, Health, Acquisition, Clinician, Environment, Digital health, Adolescent community reinforcement approach, Partnership, Hospital, EHR, IKS, Investment, Patient, Pharmaceutical industry, Abridge, KLAS, CARY

DALLAS and CARY, N.C., Oct. 31, 2023 /PRNewswire/ -- IKS Health, the premier global solution that revitalizes the clinician-patient relationship while empowering healthcare organizations to thrive, today announced the acquisition of AQuity Solutions, a Best in KLAS industry leader in tech-enabled clinical documentation, medical coding, and revenue integrity solutions for healthcare, as a wholly-owned subsidiary for $200 million.

Key Points: 
  • This acquisition advances IKS Health's Care Enablement Platform, consisting of technology and service offerings that span Revenue Optimization, Clinical Support, Value-based care, and Digital Health solutions.
  • Specifically, AQuity's rich datasets enable IKS to rapidly mature and scale its proprietary AI solutions with critical expertise and guidance from Reinforced Learning Through Human Feedback (RLHF).
  • By alleviating these administrative, clinical, and financial burdens, IKS empowers clinicians to focus on their core purpose: delivering exceptional care.
  • As margin pressures increase, IKS also helps healthcare enterprises meet the moment with advanced, proactive solutions that reduce costs and increase top line growth.

George Washington University Webinar to Discuss Combatting Clinician Burnout with Emergent Infections

Retrieved on: 
금요일, 10월 27, 2023
Policy, George Washington University School of Medicine & Health Sciences, CME, Drexel University College of Medicine, MPH, Health, SMHS, Family, Molina Healthcare, PCP, HIV, International Severe Acute Respiratory and emerging Infection Consortium, Drexel University, Gilead Sciences, COVID, COVID-19, Clinician, Health care, GW, Patient, Communication, Infection, Pharmaceutical industry, Doctor of Education, MD

WASHINGTON, Oct. 27, 2023 /PRNewswire/ -- The George Washington University School of Medicine and Health Sciences (SMHS) is hosting a free webinar on November 1st to discuss the issue of clinician burnout and how it can be addressed through emergent infections. The webinar is a part of a training series for the Two in One: HIV + COVID Screening and Testing Model, a national medical education program, and will feature Leon McCrea II, MD, MPH, senior associate dean of diversity, equity and inclusion at Drexel University, and Annette Gadegbeku, MD, associate dean of community health at Drexel University College of Medicine and an associate professor in the department of family, community & preventive medicine and chief of the division of community health.

Key Points: 
  • Training series highlights solutions for HIV, PrEP/PEP and COVID-19 vaccine screenings
    WASHINGTON, Oct. 27, 2023 /PRNewswire/ -- The George Washington University School of Medicine and Health Sciences (SMHS) is hosting a free webinar on November 1st to discuss the issue of clinician burnout and how it can be addressed through emergent infections.
  • The event is entitled "Combating PCP Burnout with Emergent Infections."
  • During the webinar, attendees will learn about emergent infections that clinicians have had to become familiar with; learn how to recognize signs of clinician burnout; and list strategies to combat clinician burnout through addressing a range of emergent infections.
  • The program is actively engaged in formulating policy recommendations for adjusting clinical guidelines on COVID vaccine, HIV and PrEP/PEP screenings.

Blueprint Releases U.S.' Largest Report on Anxiety & Depression; Introduces New Data-Driven Benchmarks for Behavioral Health Organizations

Retrieved on: 
수요일, 10월 11, 2023
Doctor of Philosophy, Anxiety, Alphabet song, Clinician, Organization, Culture, Communication, Insurance, Mental, Mental health, APA, Trauma, BQI, LMHC, Depression, Exercise, Patient, Sleep, Research institute, Software, Blueprint, Patient-Centered Outcomes Research Institute, STAR, Pharmaceutical industry, Nursing, Music, Medical imaging

CHICAGO, Oct. 11, 2023 /PRNewswire/ -- Blueprint, the technology platform helping mental health clinicians deliver higher-quality care in less time, today released the first-ever national benchmark standards of care, offering clinicians a roadmap to measure the efficacy of treatment and improve patient outcomes. The Blueprint Quality Index (BQI) provides the industry with transformative insights compiled from over 2.5 million outcome measures from 200,000 patients across more than 2,000 mental health organizations. The BQI is 50 times larger than the most well-known and largest behavioral health clinical study from 2008, STAR*D, making it the most robust, most distributed, and highest-fidelity mental health report in United States history.

Key Points: 
  • The BQI is 50 times larger than the most well-known and largest behavioral health clinical study from 2008, STAR*D , making it the most robust, most distributed, and highest-fidelity mental health report in United States history.
  • An average of two-thirds (66%) of people who begin a 12-week course of outpatient behavioral health services do not reach remission for anxiety or depression.
  • Blueprint will release a new anxiety and depression data and benchmark report annually to capture the latest industry data and provide up-to-date recommendations.
  • For more on Blueprint and its anxiety and depression data and benchmark report, please visit: https://resources.blueprint-health.com/blueprint-quality-index-2023 .